Latest News

Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan




GAITHERSBURG, Md. & OSAKA, Japan–(BUSINESS WIRE)–Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK), today announced a partnership for the development, manufacturing and commercialization of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate, in Japan. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle techn

Source link

Related posts

Silk Road Medical upsizes IPO

Newsemia

Pancreas on a Chip to Study Causes and Treatments of Diabetes

Newsemia

Major diagnostic machines lying out of order at NICVD Larkana

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World